CClinicalTrials.gg
CompletedNCT00804505Updated Dec 23, 2009

Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study

An interventional study of SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens and SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens in Corneal Disease and Hypersensitivity, sponsored by SynergEyes, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-12-23.

Sponsored by SynergEyes, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied:

  • within the corresponding range of lens powers
  • in a population randomized within multiple investigational sites
  • with a study ration of 2/1 test vs control lenses
  • for a duration of 90 days.
Read the detailed description

The objective of the study is to compare the SynergEyes SA Hybrid Contact Lens (Test) to the SynergEyes A Hybrid Contact lens (Control) when used in a daily wear regimen on non-diseased eyes for the correction of myopia (-0.25 to -6.00Diopters) with up to -2.50 Diopters of astigmatism. The population will be randomized into a 2/1 ratio of the Test/Control for 90 days. The study objective is to complete at least 40 subjects in the Test material and 20 subjects in the Control material.

The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied within the corresponding range of powers in a population randomized within investigational sites to produce a 2/1 ratio of Test vs. Control lenses.

02

Conditions studied

  • Corneal Disease
  • Hypersensitivity

Keywords

  • Substantial equivalence to control device
03

In context

Corneal Diseases

130 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.

This study's enrollment of 98 is above the median of 32 across 78 interventional studies indexed under Corneal Diseases.

Browse Corneal Diseases studies →

Lead sponsor

SynergEyes, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Prior to being considered eligible to participate in this study, each subject MUST:

  1. Be at least 18 years of age as of the date of evaluation.
  2. Have

    1. read the Informed Consent,
    2. been given an explanation of the Informed Consent,
    3. indicated an understanding of the Informed Consent and
    4. signed the Informed Consent Form.
  3. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  4. Be a current contact lens wearer.
  5. Possess wearable and visually functional eyeglasses.
  6. Be in good general health, based on his/her knowledge.
  7. Require spectacle lens powers between plano and -6.00 diopters sphere with no more than -2.50 diopters of spectacle refractive astigmatism and be willing to wear lenses in both eyes.
  8. Have manifest refraction visual acuity equal to or better than 20/25 in each eye.

Exclusion criteria

Exclusion Criteria:

  • Subjects may not be enrolled into the study if ANY of the following apply:

    1. Subject is wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may NOT wear monovision lenses at any time during the study as it will interfere with the distance visual acuity measurement.
    2. Subject exhibits poor personal hygiene.
    3. Subject is currently or within 30 days prior to this study has been an active participant in another clinical study.
    4. Subject is currently pregnant (to the best of the subject's knowledge), is planning a pregnancy within the next 3 months or is lactating.
    5. Subject is a member, relative or household member of the office staff, including the investigator(s).
    6. Subject has a known sensitivity to ingredients used in contact lens care products or over-the-counter lubricants and artificial tears.
    7. Subject has undergone refractive surgery or is currently receiving or has previously received orthokeratology treatment.
    8. Subject is aphakic or pseudophakic.
    9. Subject has ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome lupus erythematosus, scleroderma, keratoconus or type II diabetes.
    10. Use of ocular medications for any reason or systemic medications which might interfere with contact lens wear.
    11. A known history of corneal hypoesthesia (reduced corneal sensitivity).
    12. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

      • History of corneal ulcer, corneal infiltrates or fungal infections
      • Corneal scars within the visual axis
      • Pterygium
      • Dry eye symptoms with decrease tear levels and punctate staining ≥ Grade 2
      • Neovascularization or ghost vessels > 1.5 mm in from the limbus
      • Seborrhoeic eczema, seborrhoeic conjunctivitis
      • History of papillary conjunctivitis that has interfered with lens wear or a current condition of Grade 2 (Mild) or greater
    13. Clinically significant (Grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures.

TO BE ELIGIBLE TO BE RANDOMIZED FOR STUDY PRODUCT TRIAL A SUBJECT MUST HAVE ALL OF THE INCLUSION CRITERIA AND NONE OF THE EXCLUSION CRITERIA PRESENT.

TO BE ELIGIBLE FOR LENS DISPENSING, THE SUBJECT'S STUDY DEVICE CONTACT LENS VISUAL ACUITY MUST BE EQUAL TO OR BETTER THAN 20/30 IN EACH EYE

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    1

    Test arm daily wear hybrid contact lens.

    Device: SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens

  • Other
    2

    Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens

    Device: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens

Interventions

  • DeviceSynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens

    Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.

  • DeviceSynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens

    Comparison to test lens: Daily use for minimum 8 hours up to 90 days.

06

What researchers measure

Primary outcomes

  1. Comparison of objective findings (slit lamp, lens fitting, deposits, subjective symptoms, adverse events test vs control

    Time frame: 3 months

  2. Visual acuity comparison test/control.

    Time frame: 3 mo.

07

Study locations

8 sites
  • Carmel Mountain Vision Care
    San Diego, California 92129, United States
  • Silicon Valley Eye Physicians
    Sunnyvale, California 94087, United States
  • Casazza Optometric Group
    Andover, Massachusetts 01810, United States
  • Vision Care Associates
    East Lansing, Michigan 48823, United States
  • Western Reserve Vision Care, Inc.
    Beachwood, Ohio 44122, United States
  • Dr. Karambelas & Associates
    Providence, Rhode Island 02906, United States
  • Primary Eyecare Group P.C.
    Brentwood, Tennessee 37027, United States
  • Snowy Range Vision Center
    Laramie, Wyoming 82070, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 23, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00804505
Lead sponsor
SynergEyes, Inc.
First posted
Dec 9, 2008
Start date
Jun 2008
Primary completion
Nov 2008
Completion
Dec 2008
Last update
Dec 23, 2009

Study contacts

William Gleason, OD
study director · Foresight Regulatory Strategies, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion